BioSpace News Archive

Gain Therapeutics, Inc. announced that the company’s Chief Executive Officer, Eric Richman, will present and host one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place May 23-25 in Miami, Florida.

electroCore, Inc. will be presenting at the H.C. Wainwright Global Investment Conference and LD Micro Invitational Conference.

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first subject has been dosed in its three-part Phase 1 clinical trial.

BioSyent Inc. released its financial results for the three months ended March 31, 2022.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Veloxis Pharmaceuticals, Inc. , an Asahi Kasei company, today announced that the first participant has been dosed in a Phase 1 Study of VEL-101 [ NCT05238493 ]. VEL-101 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

Alcyone Therapeutics Inc. (“Alcyone”), a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions, today presents preclinical data showing the Company’s partnered novel adeno associated virus serotype 9 (AAV9) gene therapy vector ACTX-101.

LifeScan, a world leader in blood glucose monitoring, today announced recruitment for a new study that will evaluate the clinical and economic value of using the digital health subscriptions offered through OneTouch® Solutions for people with type 2 diabetes.

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the first quarter of 2022 and provided a corporate update.

RhoVac AB (“RHOVAC”) today, 18th May 2022, announces preclinical findings from its collaboration with St. John’s Research Institute (SJRI), a unit of CBCI Society for Medical Education, in Bangalore India.